No­vo Nordisk's new obe­si­ty da­ta tip the scales in semaglu­tide's fa­vor as land­mark piv­otal pro­gram looms

No­vo Nordisk has rolled out new da­ta points to back its be­lief that their new­ly ap­proved GLP-1 di­a­betes drug semaglu­tide al­so has the in­side track on a block­buster des­ig­na­tion for obe­si­ty.

No­vo’s re­searchers took cen­ter stage at the En­docrine So­ci­ety’s an­nu­al con­fer­ence in Chica­go with a new round of Phase II num­bers show­ing that the drug spurred weight loss of up to 13.8% among a group of obese adults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER